OncoMatch/Clinical Trials/NCT07435454
Exploratory Clinical Trial of Oral Paclitaxel Plus Radiotherapy in Patients With Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma
Is NCT07435454 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies non-drug interventions for locally advanced unresectable esophageal squamous cell carcinoma.
This study aims to investigate the safety and efficacy of oral paclitaxel combined with radiotherapy in the treatment of locally advanced unresectable esophageal squamous cell carcinoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Esophageal Carcinoma
Disease stage
Required: Stage CTXN+M0, CT2-T4ANXM0
Histologically confirmed locally advanced unresectable esophageal squamous cell carcinoma (cTXN+M0 or cT2-T4aNXM0). Direct tumor invasion into adjacent organs, such as the aorta or trachea (i.e., T4b disease) [excluded].
Prior therapy
Cannot have received: chemotherapy
Cannot have received: radiotherapy
Cannot have received: systemic anticancer therapy
Lab requirements
Blood counts
anc ≥ 1500/μl, platelet count ≥ 100,000/μl, and hemoglobin ≥ 9.0 g/dl or ≥ 5.6 mmol/l
Kidney function
creatinine ≤ 1.5 × uln; or for patients with creatinine > 1.5 × uln, measured or calculated creatinine clearance ≥ 60 ml/min
Liver function
total bilirubin ≤ 1.5 × uln; or for patients with total bilirubin > 1.5 × uln, direct bilirubin ≤ uln provided alt/ast ≤ 2.5 × uln and albumin ≥ 3.0 g/dl
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify